Advertisement
Dr. Mark Nestor, the Symposium chair, will be presenting "Cytokinins:Cutaneous Aging and Rosacea" at 4:45 PM.
Based on positive results demonstrated in previous studies ofPyratine-6(TM) (0.1% furfuryl tetrahydropyranyladenine) for the remediation ofphotodamaged skin and erythema, with resulting reduction in facial redness andfine wrinkles in as early as two weeks, Senetek initiated a clinical trial forassessing the effects of Pyratine-XR(TM) (0.125% furfuryltetrahydropyranyladenine) in improving the clinical signs and symptoms ofrosacea.
Advertisement
According to the National Rosacea Society, more than 14 million Americanshave rosacea, yet only a small fraction are being treated. The chronic skindisease can affect adults and children of any skin type. While the cause isunknown and there is no cure, scientific advancements are now offering rosaceasufferers hope and a way to control the signs and symptoms of this potentiallylife-disruptive disorder.
Eighteen subjects with mild-to-moderate rosacea participated in a 48-weekstudy at the University of California, Irvine, and were evaluated throughphysician assessments of inflammatory lesion count (papules and pustules),severity of erythema (redness) and telangiectasia (spider veins) and overallclinical improvement, as well as through patient assessments of signs andsymptoms of rosacea and skin tolerance.
Data suggests that Pyratine-XR(TM) may offer important advantages overcurrently available treatments for rosacea, primarily oral and topicalantibiotics, which involve long-term tolerability and other health concerns.Pyratine-XR(TM) produced a progressive decrease in the symptoms associatedwith rosacea including redness and lesions. All subject self-assessmentsshowed good tolerability and cosmetic acceptability.
After 48 weeks, there was overall clinical improvement in 80% of subjects,including reduction of erythema and papules. The investigators saw continual,statistically significant mean improvement with Pyratine-XR(TM) treatment,including a 90% improvement in lesions, 45% improvement in erythema and a 28%improvement in telangiectasia. The product was well tolerated, and in anearlier assessment of 24 patients, there was a 41% mean improvement in skindryness as early as week four, with results continuing to improve over the 48-week period. Pyratine-XR(TM) produced a significant improvement in skinbarrier function at weeks 4 through 48 as measured by a decrease in water lossfrom the skin.
"We are incredibly pleased with the results reported in this rosacea-specific study, with continual improvement in lesions, redness and spiderveins. Unlike current therapies, Pyratine-XR(TM) was well tolerated by allpatients, and offers hope to a myriad of individuals suffering from facialredness, acne lesions and spider veins, such as those afflicted with eczema,atopic dermatitis and rosacea. We are pleased that the study results are beingpresented by Dr. Nestor at this prestigious meeting," said Frank J. Massino,Chairman and CEO of Senetek PLC. "The clinical trials are extremely promising,and we anticipate a tremendous physician and patient response to Pyratine-XR(TM), which will officially launch at the American Academy of Dermatology's67th Annual Meeting in San Francisco, March 6-10, 2009."
About Senetek, PLC
Senetek PLC (OTC Bulletin Board: SNKTY) is a life sciences company engagedin the development of breakthrough technologies that target the science ofhealthy aging. The company's extensive research collaborations have resultedin a strong pipeline of patented compounds and products with broad therapeuticapplications and a leading presence in dermatology. Senetek collaborates withestablished specialty pharmaceutical companies in the final development andmarketing of its proprietary products, most recently resulting in thedevelopment of kinetin, the best-selling anti-aging product sold in the NorthAmerican physician market. For more information, visit the company's websiteat http://www.senetekplc.com.
About Dr. Mark S. Nestor
Mark S. Nestor, M.D., Ph.D. is a board-certified dermatologist anddermatologic surgeon, and director of the Center for Cosmetic Enhancement inAventura, Florida. Dr. Mark Nestor currently serves as President of theAmerican Society for Photodynamic Therapy, and as a Volunteer AssociateProfessor of the University of Miami, Miller School of Medicine. He is theimmediate Past President of the International Society of Cosmetic and LaserSurgeons.
SOURCE Senetek, PLC
